Meet Alecia Wesner, a hero for T1D clinical trials
Since 2014, Alecia Wesner has participated in numerous T1D clinical trials, many of which were early artificial pancreas system trials.
Vertex launches pivotal trial for stem-cell derived islet therapy
Vertex announced the first stem cell-derived islet therapy is entering a phase 3 clinical trial for type 1 diabetes.
Novel way to protect transplanted cells shows promise
A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential to help beta cell transplants survive in people with type 1 diabetes (T1D) with fewer side effects. The first data from this Breakthrough T1D-funded study suggests it does. The study was presented at the 5th […]
Breakthrough T1D shares the latest research at ISPAD
At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers, academics, and members of industry gathered to share the latest and greatest in diabetes research. Breakthrough T1D leaders and many of our funded researchers and collaborators were on hand —for ISPAD’s 50th birthday—to share new […]
Breakthrough T1D and the Nobel Prizes: Connected!
It’s early October, which means the Nobel Prizes are being awarded in several categories. These prestigious awards recognize outstanding contributions in Peace, Literature, Physics, Chemistry, Physiology or Medicine, and Economic Sciences. They go to the best and brightest people with the best and brightest ideas. This year, the prizes recognize work that is, in several […]
New ICD-10 Codes Will Help the T1D Community
On October 1st, the T1D community got a big win: the Centers for Medicare and Medicaid Servies (CMS) introduced a unique ICD-10 code for stage 2 type 1 diabetes (T1D). This addresses a significant gap in clinical care. Prior to this change, clinicians had limited options for coding stage 2 T1D, which resulted in inaccurate […]
At ADA 2024, Breakthrough T1D-funded research takes center stage
Here is Aaron J. Kowalski, Ph.D., C with the key takeaways from the conference and below is a written summary of Breakthrough T1D highlights.
ADA Takeaways: Day 2
At the ADA Scientific Sessions, scientists will present the latest T1D research, all with the goal of improving lives for the T1D community.
Breakthrough T1D spearheads the formation of monitoring guidelines
We spearheaded an effort to develop the first internationally agreed-upon guidance for anyone who tests positive for T1D autoantibodies.
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
